香港主板上市公司福建海西新药创制股份有限公司(股票代码：2637)董事会公告，于2025年10月24日动用闲置资金分别认购由Essence Global Investment Limited发行的基金挂钩票据，认购本金2亿港元，以及最多2亿港元的China Rock Fund SPC。该两项认购构成须予披露交易，最高适用百分比率超过5%但低于25%，需遵守香港上市规则第14章中的通知及公告规定。
基金挂钩票据期限为三年，将于2028年10月27日到期，与Generations Capital Management SP的投资回报挂钩。该产品最终贖回金额与产品所投资基金获利、管理费用及赎回成本等直接相关。China Rock Fund SPC为保本产品，预期年化回报率2.5%至6.0%，投资范围包括短期优质货币市场工具与现金等价物，允许随时赎回。
董事会指出，此次认购是根据集团可用于资金管理的盈余现金及预期投资回报条款经公平磋商后达成。相关认购旨在提高资本收益，同时兼顾保证资金安全与流动性的核心目标。董事会认为，此项交易条款公平合理，符合公司及股东整体利益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.